Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

TSXV:XRTX - Post Discussion

XORTX Therapeutics Inc > Nasdaq IPO Fund Managers turning XRX in Piss'Doff Pharma
View:
Post by SpaceLabs on Nov 24, 2021 9:34pm

Nasdaq IPO Fund Managers turning XRX in Piss'Doff Pharma

Boiler Operatives from the IPO Fund Managers office from Calgary STRIP MALL come here to Preach and Bark ! , only interested in our XRX rat poisoned shares like SHARKS, don't listen to AB42.

The FACT remains that Alex stated in his recent POSTS on BB about Dr. CEO to get his azz in gear and get the Med out there soon.

This is the only thing that will prevent XRX from DELISTING on Nasdaq bcos the SHORTERS/Manipulators are the Cheap IPO FUNDIES on 40th?
Comment by ACTIONK on Nov 25, 2021 8:54am
When looking at a company there are many things to consider when investing, or if you are a gamblier just make noise and call people names.  When reviewing this company as a whole - it currently sits at a valuation of $6.58 per share. With a EPS/P/E at 0.87 and 5 respectively. the earnings yield (EY)  at 20%. This is a super cheap company (~50% sale) and if you haven't been buying ...more  
Comment by younginvestor27 on Dec 09, 2021 12:08pm
Could you expand on this in more detail on how you came to these oonclusions?  How do you review a company like this as a whole?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities